Shattuck Labs, Inc. — fact timeline

Shattuck Labs, Inc. entered into Underwriting Agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as the representatives of the underwriters (effective 2026-06-09).

“On June 9, 2026, Shattuck Labs, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as the representatives of the underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,879,376 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) at a public offering price of $4.00 per share and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 7,870,624 shares of the Company’s Common Stock (the “Pre-Funded Warrants”) at a public offering price of $3.9999 per share, which represents the per share public offering price for the Common Stock less the $0.0001 per share exercise price for each Pre-Funded Warrant (the “Offering”).”

Shattuck Labs, Inc. shareholders approved Approval of Amendment and Restatement of the 2020 Equity Incentive Plan.

“Proposal 5. Approval of Amendment and Restatement of the 2020 Equity Incentive Plan 43,498,166 10,709,563 17 10,607,421”

Shattuck Labs, Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation.

“1 Year 2 Years 3 Years Abstentions Broker Non-Votes Proposal 4. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation 53,948,458 21,627 237,643 18 10,607,421”

Shattuck Labs, Inc. shareholders approved Advisory Vote on Executive Compensation.

“Proposal 3. Advisory Vote on Executive Compensation 49,849,887 4,356,199 1,660 10,607,421”

Shattuck Labs, Inc. shareholders approved Ratification of KPMG LLP as Independent Auditor.

“Proposal 2. Ratification of KPMG LLP as Independent Auditor 64,802,807 7,317 5,043 0”

Shattuck Labs, Inc. shareholders approved Election of Class III Director Nominees.

“Proposal 1. Election of Class III Director Nominees • Taylor Schreiber, M.D., Ph.D. 51,347,234 2,860,512 10,607,421 • Helen M. Boudreau 50,110,095 4,097,651 10,607,421 • Clay Siegall, Ph.D. 50,388,129 3,819,617 10,607,421”

Shattuck Labs, Inc. reported first quarter ended March 31, 2026 results: net income $14.8 million for the quarter ended March 31, 2026, or $0.13 per basic and diluted share, EPS $0.13 per basic and diluted share.

“Shattuck Labs Reports First Quarter 2026 Financial Results”

Shattuck Labs, Inc. reported financial results for the year ended December 31, 2025.

“On March 5, 2026, Shattuck Labs, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”

Shattuck Labs, Inc. entered into Sales Agreement with Leerink Partners LLC valued at $75,000,000 (effective 2026-01-22).

“On January 22, 2026, Shattuck Labs, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock, $0.0001 par value per share (the “Shares”), through the Agent. The offering and sale of up to $75,000,000 of the Shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-292697) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on January 13, 2026 and declared effective by the SEC on January 21, 2026, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on January 22, 2026.”

Shattuck Labs, Inc. announced a restructuring with charges of between $1.5 million and $1.75 million affecting SL-172154 program (approximately 40% of Shattuck's workforce).

“On October 1, 2024, pursuant to previous authorization by the Board of Directors of the Company, an authorized officer of the Company approved a restructuring plan to prioritize the development of the Company’s DR3 program. The plan is intended to optimize the Company’s cost structure by aligning the size and structure of its workforce with the Company’s current goals and strategy. The organizational realignment includes discontinuing the Company’s SL-172154 program in view of overall survival data readouts from its studies in higher-risk myelodysplastic syndromes and acute myeloid leukemia. Approximately 40% of Shattuck’s workforce will be impacted by the changes. The Company expects to complete the reduction in force in the fourth quarter of 2024. As a result of these changes, the Company expects to incur restructuring charges between $1.5 million and $1.75 million, the majority of which are related to employee severance costs.”

Shattuck Labs, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $18.5 million for the quarter ended March 31, 2024, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share.

“Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended March 31, 2024 and provided recent business highlights.”

Dr. Clay Siegall was appointed as Class III director at Shattuck Labs, Inc..

“On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.”

Dr. Kate Sasser was appointed as Class II director at Shattuck Labs, Inc..

“On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.”

Shattuck Labs, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent business highlights.”

Shattuck Labs, Inc. entered into Collaboration Agreement with Ono Pharmaceutical Co., Ltd valued at Up to $9 million in upfront and milestone payments for research plan, plus potential milestone payme (effective 2024-02-13).

“On February 9, 2024, Shattuck Labs, Inc. (“Shattuck”) entered into a collaboration and license agreement (the “Collaboration Agreement”) with Ono Pharmaceutical Co., Ltd (“Ono”), effective February 13, 2024, pursuant to which Shattuck and Ono will collaborate in the research and preclinical development of certain prespecified compounds directed toward a pair of targets selected by Ono from Shattuck’s pipeline of bifunctional fusion proteins (the “Development Compounds”).”

Shattuck Labs, Inc. entered into Registration Rights Agreement with Purchasers valued at Company will register resale of shares issuable upon exercise of pre-funded warrants (effective 2023-12-21).

“Also on December 21, 2023, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers, which provides that the Company will register the resale of the shares of Common Stock issuable upon the exercise of the pre-funded warrants.”

Shattuck Labs, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at pre-funded warrants to purchase 3,100,823 shares of common stock at $6.4499 per pre-funded warrant (effective 2023-12-21).

“Also on December 21, 2023, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”) pursuant to which the Purchasers agreed to purchase pre-funded warrants to purchase 3,100,823 shares of Common Stock at a purchase price of $6.4499 per pre-funded warrant, which represents the per share public offering price of the Common Shares less the $0.0001 per share exercise price for each pre-funded warrant (the “Private Placement”).”

Shattuck Labs, Inc. entered into Underwriting Agreement with Evercore Group L.L.C. valued at 4,651,163 shares of common stock at $6.45 per share (effective 2023-12-21).

“On December 21, 2023, Shattuck Labs, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Evercore Group L.L.C., as the representative of the underwriters named therein (the “Underwriters”) relating to the offering, issuance and sale (the “Offering”) of 4,651,163 shares (the “Common Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a public offering price of $6.45 per share (the “Offering”).”

Shattuck Labs, Inc. reported financial results for the quarter ended September 30, 2023.

“On November 9, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.”

Shattuck Labs, Inc. reported financial results for quarter ended June 30, 2023.

“On August 10, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.”

Shattuck Labs, Inc. shareholders approved Ratification of KPMG LLP as Independent Auditor at the 2023-05-23 meeting.

“Proposal 2. Ratification of KPMG LLP as Independent Auditor 36,301,756 6,398 4,783 0”

Shattuck Labs, Inc. shareholders approved Election of Class III Director Nominees at the 2023-05-23 meeting.

“Proposal 1. Election of Class III Director Nominees • Helen M. Boudreau 26,689,880 1,007,139 8,615,918 • Taylor Schreiber, M.D., Ph.D. 26,686,925 1,010,094 8,615,918”

Shattuck Labs, Inc. reported financial results for the quarter ended March 31, 2023.

“On May 9, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.”

Shattuck Labs, Inc. reported financial results for the three months and year ended December 31, 2022.

“On February 23, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the three months and year ended December 31, 2022.”

Shattuck Labs, Inc. reported the quarter ended September 30, 2022 results: net income ($0.58) per basic and diluted share, EPS $0.58 per basic and diluted share.

“Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2022”

Dr. Carrie Brownstein was appointed as Director at Shattuck Labs, Inc..

“On October 22, 2021, the Board appointed Dr. Carrie Brownstein as a member of the Board, effective immediately.”

George Golumbeski was appointed as Chairman of the Board at Shattuck Labs, Inc..

“The Board appointed independent director George Golumbeski to replace Mr. Hornblower as Chairman of the Board.”

Josiah Hornblower resigned as Chairman of the Board at Shattuck Labs, Inc..

“On October 22, 2021, Josiah Hornblower notified the board of directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) of his intent to resign as a director and Chairman of the Board, effective as of such date.”